Entry
Name
Amplified FGFR to RAS-ERK signaling pathway
Definition
FGFR* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK
Expanded
(2260v1,2263v1) -> 2885 -> (6654,6655) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595)
Class
Type
Variant
Pathway
Disease
Gene
2260 FGFR1; fibroblast growth factor receptor 1
2263 FGFR2; fibroblast growth factor receptor 2
2885 GRB2; growth factor receptor bound protein 2
6654 SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1
6655 SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2
3265 HRAS; HRas proto-oncogene, GTPase
3845 KRAS; KRAS proto-oncogene, GTPase
4893 NRAS; NRAS proto-oncogene, GTPase
369 ARAF; A-Raf proto-oncogene, serine/threonine kinase
673 BRAF; B-Raf proto-oncogene, serine/threonine kinase
5894 RAF1; Raf-1 proto-oncogene, serine/threonine kinase
5604 MAP2K1; mitogen-activated protein kinase kinase 1
5605 MAP2K2; mitogen-activated protein kinase kinase 2
5594 MAPK1; mitogen-activated protein kinase 1
5595 MAPK3; mitogen-activated protein kinase 3
Variant
2260v1 (FGFR*) FGFR1 amplification
2263v1 (FGFR*) FGFR2 amplification
Reference
Authors
Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
Title
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
Journal
Reference
Authors
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A
Title
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Journal
Reference
Authors
Katoh M, Nakagama H
Title
FGF receptors: cancer biology and therapeutics.
Journal
Reference
Authors
Katoh M
Title
FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies.
Journal
Reference
Authors
Katoh M
Title
Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.
Journal
LinkDB
All DBs